证券之星消息，10月30日化学制药板块较上一交易日下跌1.28%，翰宇药业领跌。当日上证指数报收于 3986.9，下跌0.73%。深证成指报收于13532.13，下跌1.16%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300255 | 常山药业 | 7451.52万 | 2.43% | -6875.79万 | -2.24% | -575.73万 | -0.19% | | 688759 | C必贝特 | 5872.22万 | 8.02% | 166.62万 | 0.23% | -6038.84万 | -8.25% | | 600079 | 人福医药 | 5403.96万 | 6.70% | -8584.67万 | -10.64% | ﺍﻟﻤﻮﺍﻗﻊ ﺍﻟﻤﺴﺘ 3180.72万 | 3.94% | | 603707 | 健友股份 | 4874.92万 | 14.52% | -12 ...

Core Insights - The company reported significant growth in its financial performance for the first three quarters of 2025, with revenue reaching 683 million yuan, a year-on-year increase of 82.06%, and a net profit of 71.35 million yuan, marking a turnaround from losses [1] - The operational cash flow reached a historical high of 271 million yuan, reflecting a year-on-year growth of 207.37%, driven by the successful market penetration of its core product, liraglutide injection [1] Financial Performance - Revenue for the first three quarters was 683 million yuan, up 82.06% year-on-year [1] - Net profit attributable to shareholders was 71.35 million yuan, indicating a return to profitability [1] - Operating cash flow was 271 million yuan, representing a 207.37% increase year-on-year, the highest in the same period historically [1] Technological Innovation - The company launched a "Peptide AI Process Optimization Assistant" in collaboration with Huawei Cloud, utilizing over 100,000 historical process data points and global chemical databases to enhance drug development efficiency [2] - The AI assistant has reportedly reduced research and development cycles by 45% and lowered trial and error costs by over 20% [2] - The company is also advancing in new peptide sustained-release technologies, improving drug delivery convenience and optimizing drug action duration [2] CRDMO Business Expansion - The company has been active in the CRDMO (Contract Research, Development, and Manufacturing Organization) sector, forming strategic partnerships to enhance its business ecosystem [3] - Collaborations with Carbon Cloud Peptide focus on innovative peptide drug development, covering the entire process from preclinical research to commercialization [3] - The partnership with Borui Pharmaceutical aims to provide international standard raw material supply for oral peptide products, supporting global industrialization of innovative drugs [3] Capital Increase and Capacity Expansion - The company announced a plan to raise up to 968 million yuan through a private placement to enhance its core peptide drug business [4] - Of the raised funds, 495 million yuan will be allocated to expanding peptide drug production lines and green intelligent upgrades to ensure continuous supply of raw materials [4] - The plan also includes investing 40 million yuan in expanding peptide fragment production, aiming for vertical integration in the pharmaceutical supply chain [4]

北京商报讯（记者 丁宁）10月29日晚间，翰宇药业（300199）发布2025年三季报显示，公司前三季度 营业收入6.83亿元，同比增长82.06%；归属净利润7135.15万元，同比增长305%。 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-057 深圳翰宇药业股份有限公司 关于变更公司高级管理人员暨调整 董事会提名委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于董事、副总裁兼董事会秘书辞职的情况 深圳翰宇药业股份有限公司（以下简称"翰宇药业"或"公司"）董事会于2025 年10月28日收到公司董事、副总裁兼董事会秘书杨笛女士提交的书面辞职报告。 杨笛女士因个人原因，向董事会提出辞去董事、副总裁、董事会秘书职务，原定 任期至第六届董事会届满之日止，辞去职务后杨笛女士将不再担任公司及子公司 任何职务。杨笛女士的辞职报告自送达公司董事会之日起生效。 李娉娉女士已取得深圳证券交易所颁发的《董事会秘书资格证书》，具备履 行职责所必需的专业能力，熟悉履职相关的法律法规，具备与岗位要求相适应的 职业操守及相应的专业胜任能力与从业经验，其任职符合《公司法》《深圳证券 交易所上市公司自律监管指引第2 号——创业板上市公司规范运作》等相关法律 和《公司章程》等规定。 李娉娉女士联系方式如下： 1、电话：0755-2658803 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-055 深圳翰宇药业股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 本次会议于 2025 年 10 月 28 日下午 15:30 在公司龙华总部 2006 董事会会议 室以现场结合通讯方式召开。会议应出席董事 9 人，实际出席会议董事 9 人，其 中董事 PINXIANG YU 女士、唐洋明先生、杨笛女士、独立董事胡文言先生、许 立勇先生以通讯表决方式出席会议。本次会议由董事长曾少贵先生召集和主持， 公司监事及高级管理人员列席了本次会议。 本次会议的召集、召开符合《中华人民共和国公司法》和《公司章程》的有 关规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司<2025年第三季度报告>的议案》； 经审核，董事会认为：编制和审核深圳翰宇药业股份有限公司 2025 年第三 季度报告的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 ...

Core Viewpoint - Han Yu Pharmaceutical (300199) reported a significant increase in revenue for the first three quarters of 2025, driven by a rise in formulation income, despite a net loss in the third quarter [1] Financial Performance - The company's third-quarter revenue reached 134 million yuan, marking an 11.86% year-on-year increase [1] - The net loss for the third quarter was 74.12 million yuan, compared to a loss of 24.44 million yuan in the same period last year [1] - For the first three quarters of 2025, total revenue was 683 million yuan, reflecting an 82.06% year-on-year growth [1] - The net profit for the first three quarters was 71.35 million yuan, a turnaround from a loss of 34.81 million yuan in the previous year [1] - Basic earnings per share for the first three quarters stood at 0.08 yuan [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥133,680,763.66, an increase of 11.86% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥74,117,132.91, a decrease of 203.18% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥72,551,040.34, down 114.31% from the previous year[5] - The company's operating income for the first nine months of 2025 was ¥683,122,870.45, representing an 82.06% increase compared to the same period in 2024[11] - Total operating revenue for the current period reached ¥683,122,870.45, a significant increase from ¥375,225,390.50 in the previous period, representing an increase of approximately 82%[24] - Net profit for the current period was ¥69,758,073.47, compared to a net loss of ¥35,828,756.23 in the previous period, marking a turnaround in profitability[25] - The total comprehensive income for the current period was ¥68,916,881.64, compared to a loss of ¥36,542,670.37 in the previous period, indicating a significant improvement[26] Assets and Liabilities - The total assets as of September 30, 2025, amounted to ¥3,170,646,772.12, reflecting a growth of 5.40% compared to the end of the previous year[5] - The company's total assets increased to ¥3,170,646,772.12 from ¥3,008,225,640.09, reflecting a growth of approximately 5.4%[22] - Total liabilities rose to ¥2,504,569,909.28 from ¥2,411,179,128.07, an increase of about 3.9%[22] - The equity attributable to shareholders of the parent company improved to ¥649,150,598.16 from ¥578,626,837.31, showing an increase of approximately 12.2%[22] Cash Flow - The operating cash flow net amount for the year-to-date was ¥270,699,175.19, an increase of 207.37% year-on-year[5] - Operating cash inflow for the current period reached ¥799,866,415.70, a significant increase from ¥501,843,341.73 in the previous period, representing a growth of approximately 58.9%[27] - Net cash flow from operating activities was ¥270,699,175.19, compared to ¥88,069,613.03 in the prior period, indicating a year-over-year increase of 207.5%[27] - The net increase in cash and cash equivalents for the current period was ¥24,473,569.69, contrasting with a decrease of -¥204,507,285.80 in the previous period[28] - The ending balance of cash and cash equivalents stood at ¥117,006,412.85, compared to ¥135,428,940.64 at the end of the previous period[28] Investments and Shareholder Information - The investment income for the first nine months of 2025 was ¥2,723,249.93, a significant increase of 614.25% year-on-year[12] - The company reported an investment income of ¥2,723,249.93, a recovery from a loss of ¥529,557.23 in the previous period[25] - The total number of common shareholders at the end of the reporting period is 110,118[15] - The largest shareholder, Zeng Shaogui, holds 11.16% of shares, amounting to 98,533,635 shares, with 41,190,000 shares pledged[15] - The top ten shareholders collectively hold significant stakes, with the top three being brothers and controlling shareholders of the company[16] Research and Development - Research and development expenses for the current period were ¥74,125,204.88, up from ¥59,329,000.15, indicating a growth of about 25%[24] Operational Changes and Approvals - The company signed a series of agreements with Sanofi on August 20, 2025, marking a new phase in the commercialization of their product[17] - The company received marketing approval for Acetate Atosiban Injection in Vietnam on August 22, 2025, expanding its overseas product pipeline[18] - The company and DS3 RX LLC mutually agreed to terminate their cooperation agreement, ending all unfulfilled obligations[18] Inventory and Current Assets - Total current assets rose to ¥565,088,980.79 from ¥463,048,006.84, indicating an increase of about 22.0%[20] - Inventory increased to ¥288,158,914.76 from ¥238,630,347.88, reflecting a growth of approximately 20.9%[20] Cash Flow from Activities - Cash outflow from investment activities totaled ¥173,272,458.81, up from ¥74,866,778.32, resulting in a net cash flow from investment activities of -¥165,492,033.13, worsening from -¥28,726,078.08[28] - Cash inflow from financing activities was ¥1,107,100,971.04, down from ¥1,241,333,185.23, while cash outflow from financing activities was ¥1,189,769,767.06, compared to ¥1,507,182,727.29 in the previous period[28] - The net cash flow from financing activities improved to -¥82,668,796.02 from -¥265,849,542.06, showing a reduction in cash outflow[28] Tax and Other Income - The company received ¥24,529,820.17 in tax refunds, significantly higher than ¥6,169,638.15 in the prior period, marking an increase of approximately 297.5%[27] - The company reported cash inflow from other operating activities of ¥133,946,814.91, up from ¥55,534,396.69, reflecting an increase of about 141.5%[27] - The company’s cash inflow from investment income was ¥3,288,131.02, a notable increase from ¥614,700.24 in the previous period[27]

Group 1 - Hanyu Pharmaceutical experienced a 5.02% increase in stock price, reaching 21.97 CNY per share, with a trading volume of 655 million CNY and a turnover rate of 4.05%, resulting in a total market capitalization of 19.405 billion CNY [1] - Hanyu Pharmaceutical, established on April 2, 2003, and listed on April 7, 2011, is located in Longhua District, Shenzhen, Guangdong Province, and primarily engages in chemical pharmaceuticals and medical devices, with 100% of its revenue derived from the pharmaceutical manufacturing sector [1] Group 2 - According to data from the top ten holdings of funds, one fund under China Merchants Fund holds Hanyu Pharmaceutical as a significant investment. The fund, China Merchants Stable Growth Mixed A (010503), reduced its holdings by 500 shares in the second quarter, maintaining a total of 500 shares, which represents 0.02% of the fund's net value, ranking it as the ninth largest holding [2] - The China Merchants Stable Growth Mixed A fund was established on February 5, 2021, with a latest scale of 23.4958 million CNY. Year-to-date returns are 1.7%, ranking 7700 out of 8226 in its category, while the one-year return is 2.11%, ranking 7599 out of 8099. Since inception, the fund has achieved a return of 0.77% [2] - The fund manager, Chen Jiarong, has a tenure of 16 years and 313 days, with total assets under management of 51.3802 million CNY. The best return during his tenure is 45.74%, while the worst return is -4.97% [2]

Core Points - Han Yu Pharmaceutical announced a financing plan to raise up to 700 million RMB from Shenzhen High-tech Investment Group and its subsidiaries [2] - The financing will cover multiple products and has a term of no more than 12 months [2] - The financing will be secured by assets from the company's Pingshan branch and Dali subsidiary [2]

Core Viewpoint - The company has approved a financing proposal to raise up to RMB 700 million from Shenzhen High-tech Investment Group Co., Ltd. and its subsidiaries, with a term not exceeding 12 months [1] Financing Details - The total financing amount is capped at RMB 700 million, covering multiple products [1] - The financing will be secured by collateral from the company's Pingshan branch and Dali subsidiary [1] - The specific terms will be finalized in the actual signed contract [1]